Quadrivium 1

Quadrivium 1 is a dedicated university spinout fund managed by Seventure Partners in Paris, focused on commercializing elite academic life science research. The fund operates at the earliest stages where academic discoveries are formed into operating companies, which means founders typically come from research institutions and arrive with intellectual property, scientific publications, and a vision for translation rather than fully built commercial teams. Healthcare interest is concentrated in biotech and medical devices, both of which benefit from deep scientific origins. AI is not a stated focus.

Quadrivium 1 invests at Pre-Seed, Seed, and Series A with checks of $1M to $5M, positioning the fund to participate as a meaningful early-stage backer that can support both initial company formation and follow-on financing as scientific milestones are achieved. The geographic emphasis is France, anchored by Seventure’s Paris base and the fund’s connection to French academic institutions. Founders should expect engagement informed by Seventure’s broader life sciences network, which can be helpful for syndicate building, scientific advisory recruitment, and progression toward later rounds led by specialist biotech investors.

Named partners and specific portfolio companies are not detailed in the materials reviewed, so this profile reflects limited public information about current team contacts and named investments. Founders considering Quadrivium 1 should prepare a clear translation thesis, a defensible IP position, and a realistic plan for milestones that justify the next round of financing. A direct outreach is most effective when the team articulates the science, the institutional origin of the work, and the specific operational and capital milestones the fund’s check is intended to unlock.